BBI Life Sciences Corporation, an investment holding company, develops, manufactures, and sells various life sciences products that are used in scientific research in the People’s Republic of China, North America, South America, Europe, and Africa. It operates through five segments: DNA Synthesis Products; Genetic Engineering Services; Life Science Research Consumables; Protein and Antibody Related Products and Services; and Third Party Detection. The DNA Synthesis Products segment offers oligonucleotide synthesis products for life sciences laboratories, as well as for various applications in molecular biology and medical research; gene synthesis products for the research of genetics, the regulation of gene expression, and the functional research of gene and drug discovery. The Genetic Engineering Services segment provides DNA sequencing services; and molecular biology services comprising gene cloning, genotyping, gene expression analysis, and real-time PCR. The Life Science Research Consumables segment offers biochemical reagents and research kits, as well as lab ware, such as containers and tools for experiments to researchers. The Protein and Antibody Related Products and Services segment provides polypeptide, protein extraction, and analysis kits, as well as protein detection, analysis, expression, and purification services; and antibody related products, including polyclonal and monoclonal antibodies, and immunology-related products and antibody related kits, as well as customized antibody production and immunology experiment services. The Third Party Detection segment develops medical-related detection, as well as provides diagnosis and scientific research services. In addition, it offers management consulting services. The company primarily serves colleges, universities, research institutes, hospitals, and pharmaceutical and biotech companies. BBI Life Sciences Corporation was incorporated in 2013 and is headquartered in Shanghai, the People’s Republic of China.